FR3008619B1 - Antagonistes, agonistes partiels et agonistes inverses du recepteur de l'urotensine ii pour leur utilisation dans la prevention des deficits neurologiques consecutifs a une hemorragie sous-arachnoidienne - Google Patents

Antagonistes, agonistes partiels et agonistes inverses du recepteur de l'urotensine ii pour leur utilisation dans la prevention des deficits neurologiques consecutifs a une hemorragie sous-arachnoidienne Download PDF

Info

Publication number
FR3008619B1
FR3008619B1 FR1356995A FR1356995A FR3008619B1 FR 3008619 B1 FR3008619 B1 FR 3008619B1 FR 1356995 A FR1356995 A FR 1356995A FR 1356995 A FR1356995 A FR 1356995A FR 3008619 B1 FR3008619 B1 FR 3008619B1
Authority
FR
France
Prior art keywords
agonists
arachnoidal
urotensin
hemorrhage
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1356995A
Other languages
English (en)
Other versions
FR3008619A1 (fr
Inventor
Francois Proust
Vincent Compere
Pierrick Gandolfo
Martine Dubois
Helene Castel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Rouen
Centre Hospitalier Universitaire de Rouen
Original Assignee
Universite de Rouen
Centre Hospitalier Universitaire de Rouen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Rouen, Centre Hospitalier Universitaire de Rouen filed Critical Universite de Rouen
Priority to FR1356995A priority Critical patent/FR3008619B1/fr
Publication of FR3008619A1 publication Critical patent/FR3008619A1/fr
Application granted granted Critical
Publication of FR3008619B1 publication Critical patent/FR3008619B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR1356995A 2013-07-16 2013-07-16 Antagonistes, agonistes partiels et agonistes inverses du recepteur de l'urotensine ii pour leur utilisation dans la prevention des deficits neurologiques consecutifs a une hemorragie sous-arachnoidienne Active FR3008619B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1356995A FR3008619B1 (fr) 2013-07-16 2013-07-16 Antagonistes, agonistes partiels et agonistes inverses du recepteur de l'urotensine ii pour leur utilisation dans la prevention des deficits neurologiques consecutifs a une hemorragie sous-arachnoidienne

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1356995A FR3008619B1 (fr) 2013-07-16 2013-07-16 Antagonistes, agonistes partiels et agonistes inverses du recepteur de l'urotensine ii pour leur utilisation dans la prevention des deficits neurologiques consecutifs a une hemorragie sous-arachnoidienne
FR1356995 2013-07-16

Publications (2)

Publication Number Publication Date
FR3008619A1 FR3008619A1 (fr) 2015-01-23
FR3008619B1 true FR3008619B1 (fr) 2018-04-20

Family

ID=49546538

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1356995A Active FR3008619B1 (fr) 2013-07-16 2013-07-16 Antagonistes, agonistes partiels et agonistes inverses du recepteur de l'urotensine ii pour leur utilisation dans la prevention des deficits neurologiques consecutifs a une hemorragie sous-arachnoidienne

Country Status (1)

Country Link
FR (1) FR3008619B1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60207894T2 (de) * 2001-12-04 2006-07-20 Actelion Pharmaceuticals Ltd. 4-(piperidyl- und pyrrolidyl-alkyl-ureido)-chinoline als urotensin ii rezeptor antagonisten
AU2005293196B2 (en) * 2004-10-12 2012-03-22 Actelion Pharmaceuticals Ltd 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt
CL2007002097A1 (es) * 2006-07-20 2008-01-18 Smithkline Beecham Corp Compuestos derivados de pirrolidina o morfolina antagonistas de urotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar insuficiencia cardiaca congestiva, insuficiencia cardiaca isquemica, angina, isquemia del miocardio, vejiga hiperactiva, asma y/o copd, entre otras.

Also Published As

Publication number Publication date
FR3008619A1 (fr) 2015-01-23

Similar Documents

Publication Publication Date Title
FR2989711B1 (fr) Piece de revetement de sol pour la detection de chutes
DK2976074T3 (da) Antagonister af cannabinoid-receptoren CB1 til anvendelse ved behandling af sygdomme associeret med neuronale dendritiske anormaliteter
IL240820A0 (en) Substances that regulate a decrease in androgen receptor and their uses
IL258892B (en) Calcitonin gene-related peptide receptor antagonists
HK1220386A1 (zh) 受體拮抗劑在軟骨疾病的治療中的用途
EP2654423A4 (fr) Antagonistes azaindane carboxamides hétérocycliques fusionnés de récepteurs du cgrp
HK1249095A1 (zh) Cgrp受體拮抗劑
IL275238A (en) A liquid compound containing antagonistic VEGF
IL258894A (en) Cgrp receptor antagonists
EP2846801A4 (fr) Antagonistes de récepteur de cgrp à base de pyridine
IL244356A0 (en) Formulations for cgrp receptor antagonists
FR2985526B3 (fr) Unite de bourrage perfectionnee pour le ballast de voies ferrees
IL258893A (en) Cgrp receptor antagonists
EP2563777A4 (fr) Agonistes inverses et antagonistes neutres pour récepteur du tsh
PL2877173T3 (pl) Antagoniści receptora kannabinoidowego/agoniści odwrotni
BR112015005750A2 (pt) antagonistas peptídicos do receptor de vasopressina-2
SG11201505517TA (en) Use of selective delta-opioid receptor antagonists and specific sensory receptor ligands
FR3008619B1 (fr) Antagonistes, agonistes partiels et agonistes inverses du recepteur de l'urotensine ii pour leur utilisation dans la prevention des deficits neurologiques consecutifs a une hemorragie sous-arachnoidienne
LU92144B1 (fr) Dispositif d'ancrage mobile pour rail
FR2990859B1 (fr) Utilisation d'une molecule h4 agoniste pour le traitement de la mucoviscidose
FR3001543B1 (fr) Dispositif pour la mise sous traction ou sous compression d'une eprouvette
FR2990734B1 (fr) Bossage pour systeme pendulaire d'amortissement
HK1202459A1 (en) Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
FR2993660B1 (fr) Dispositif pour le montage d'au moins une eprouvette
EP2846800A4 (fr) Antagonistes de récepteur de cgrp hétérocycliques

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5